πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8853252

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders,

Jenrin Discovery, LLC Β· Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8840886

Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8829024

Combination steroid and glucocorticoid receptor antagonist therapy

Corcept Therapeutics Incorporated Β· Granted Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8815917

DP2 antagonist and uses thereof

Panmira Pharmaceuticals, LLC Β· Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8815907

Quaternary ammonium compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8816088

Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist

Theravance Respiratory Company, LLC Β· Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8802698

8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8802856

Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8802107

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8796291

A3 adenosine receptor antagonists and partial agonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8785442

Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof

Curegenix, Inc. Β· Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8785393

Ophthalmic pharmaceutical compositions of DP2 receptor antagonists

Panmira Pharmaceuticals, LLC Β· Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8785633

Guanidine-containing compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8778983

Polycyclic compounds as lysophosphatidic acid receptor antagonists

AMIRA PHARMACEUTICALS, INC. Β· Granted Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8772331

Small molecule antagonists of bacterial quorum-sensing receptors

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Jul 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8765125

Methods of treating autoimmune diseases with Dll4 antagonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8722896

Prokineticin receptor antagonists and uses thereof

The Regents of the University of California Β· Granted Tue May 13 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8710004

Stable liquid VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8703730

Complement antagonists and uses thereof

REGENESANCE B.V. Β· Granted Tue Apr 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8703791

3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor anta

Theravance, Inc. Β· Granted Tue Apr 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8680132

Spiro-oxindole MDM2 antagonists

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8680131

Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions,

Jenrin Discovery, LLC Β· Granted Tue Mar 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8664242

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance, Inc. Β· Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8664220

Polycyclic compounds as lysophosphatidic acid receptor antagonists

AMIRA PHARMACEUTICALS, INC. Β· Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted